IP Library › Granted Patent US 12,310,965
Granted Patent B2
US 12,310,965 · App. 17/599,472 · Granted May 27, 2025

Treatment of cancer utilizing an identified adenosine fingerprint

Inventors: Amy Elizabeth Anderson (San Mateo, CA); Devika Ashok (Belmont, CA); Daniel M. DiRenzo (Palo Alto, CA); Akshata R. Udyavar (Foster City, CA); Matthew J. Walters (Pacifica, CA); Stephen W. Young (Palomar Park, CA)
Assignee: ARCUS BIOSCIENCES, INC.
A61K31/506A61K31/706A61K31/7076A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,965
App. No.
17/599,472
Granted
May 27, 2025
Kind
B2
Abstract

The present disclosure provides methods of treating a cancer in a subject having an established adenosine fingerprint. An established adenosine fingerprint includes assessing the blood concentration of one or more adenosine machinery proteins, assessing the enzymatic activity of one or more adenosine machinery proteins, and/or assessing the tumor expression level of adenosine machinery proteins. The methods disclosed herein include administering to said subjects a therapeutic agent selected from the group consisting of an agent targeting the extracellular production of adenosine, and an agent antagonizing the activation by adenosine of one of its receptors.

Claims (13)

1. A method of inhibiting or suppressing a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD73 inhibitor,

wherein the cancer has an established adenosine fingerprint determined from a biopsy from the subject,

wherein the established adenosine fingerprint is an increase in the amount of CD73 as determined by immunostaining for CD73,

wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above a threshold value that is a CD73 staining of 1% or more of cancer cells in the biopsy or a measured value above an average value of CD73 immunostaining in biopsy samples from a population of subjects with the same type of cancer, and

wherein the CD73 inhibitor is Compound A

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the increase in the amount of CD73 as determined by immunostaining is calculated as positive staining area, percentage of positive staining cells, H-score, combined positive score, or tumor proportion score.

3. The method of claim 1 , wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above the average value of CD73 immunostaining in biopsy samples from a population of subjects with the same type of cancer.

4. The method of claim 1 , wherein the increase in the amount of CD73 as determined by immunostaining is a measured value above a threshold value, that is a CD73 staining of 1% or more of cancer cells in the biopsy.

5. The method of claim 1 , wherein the cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone, or the cancer is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, or testicular carcinoma.

6. The method of claim 1 , further comprising administering to the subject a PD1 inhibitor and/or a PD-L1 inhibitor.

7. The method of claim 6 , wherein the PD1 and/or PD-L1 inhibitor is selected from the group consisting of pembrolizumab, nivolumab, MEDI-0680, BGB-108, GB-226, PDR-001, mDX-400, SHR-1210, IBI-308, PF-06801591, atezolizumab, durvalumab, avelumab, BMS-936559, KD-033, CA-327, CA-170, ALN-PDL, TSR-042, and STI-1014.

8. The method of claim 1 , further comprising a chemotherapeutic agent, wherein the chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE SPELLING OF THE 6TH INVENTORS NAME PREVIOUSLY RECORDED AT REEL: 058615 FRAME: 0564. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 20, 2022
From: ANDERSON, AMY ELIZABETH; ASHOK, DEVIKA; DIRENZO, DANIEL M.; UDYAVAR, AKSHATA R.; WALTERS, MATTHEW J.; YOUNG, STEPHEN W.
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 061012/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2022
From: ANDERSON, AMY ELIZABETH; ASHOK, DEVIKA; DIRENZO, DANIEL M.; UDYAVAR, AKSHATA R.; WALTERS, MATTHEW J.; YOUNG, STEVE W.
To: ARCUS BIOSCIENCES, INC.
Reel/Frame 058615/0564 →
Continuity (2)
Provisional Application 62826728 · Mar 29, 2019
Related Publication 20220211701A1 · Jul 7, 2022
References Cited (94)
US 10239912B2 · Debien et al. · 2019 [cited by applicant]
US 10399962B2 · Beatty et al. · 2019 [cited by applicant]
US 10981944B2 · Debien et al. · 2021 [cited by applicant]
US 11001603B2 · Debien et al. · 2021 [cited by applicant]
US 11072597B2 · Beatty et al. · 2021 [cited by applicant]
US 11633416B1 · Lawson et al. · 2023 [cited by applicant]
US 20160129108A1 · Sachsenmeier et al. · 2016 [cited by applicant]
US 20160153053A1 · Skog et al. · 2016 [cited by applicant]
US 20170267710A1 · Debien · 2017 [cited by examiner]
US 20180125973A1 · Sachsenmeier et al. · 2018 [cited by applicant]
US 20180200378A1 · Bennett et al. · 2018 [cited by applicant]
US 20190022096A1 · Willingham et al. · 2019 [cited by applicant]
US 20190031766A1 · Prinz et al. · 2019 [cited by applicant]
US 20200405629A1 · Jaen et al. · 2020 [cited by applicant]
US 20210371449A1 · Debien et al. · 2021 [cited by applicant]
US 20210395291A1 · Pennell et al. · 2021 [cited by applicant]
US 20210395391A1 · Zhu et al. · 2021 [cited by applicant]
US 20220144808A1 · Beatty et al. · 2022 [cited by applicant]
US 20220211701A1 · Anderson et al. · 2022 [cited by applicant]
US 20220241313A1 · Tan et al. · 2022 [cited by applicant]
US 20230382942A1 · Pennell et al. · 2023 [cited by applicant]
US 20240352057A1 · Debien et al. · 2024 [cited by applicant]
WO WO03050241A2 · 2003 [cited by applicant]
WO WO2004079013A1 · 2004 [cited by applicant]
WO 2012031320 · 2012 [cited by applicant]
WO WO2015031320A1 · 2015 [cited by applicant]
WO WO2016075099A1 · 2016 [cited by applicant]
WO WO2016075176 · 2016 [cited by applicant]
WO 2017040930 · 2017 [cited by applicant]
WO WO2017120508A1 · 2017 [cited by applicant]
WO WO2017152085A1 · 2017 [cited by applicant]
WO WO2018067424A1 · 2018 [cited by applicant]
WO WO2018094148A1 · 2018 [cited by applicant]
WO WO2018136700A1 · 2018 [cited by applicant]
WO WO2018137598A1 · 2018 [cited by applicant]
WO WO2018187484A1 · 2018 [cited by applicant]
WO WO2018187508A1 · 2018 [cited by applicant]
WO WO2018187512 · 2018 [cited by applicant]
WO WO2018204661A1 · 2018 [cited by applicant]
WO WO2018213377A1 · 2018 [cited by applicant]
WO WO2018237173A1 · 2018 [cited by applicant]
WO 2019007140 · 2019 [cited by applicant]
WO WO2019090347A1 · 2019 [cited by applicant]
WO WO2019161054A1 · 2019 [cited by applicant]
WO WO2019173682A1 · 2019 [cited by applicant]
WO WO2019168744 · 2019 [cited by applicant]
WO WO2019206872A1 · 2019 [cited by applicant]
WO WO2019200256 · 2019 [cited by applicant]
WO WO2020018680A1 · 2020 [cited by applicant]
WO WO2020023846A1 · 2020 [cited by applicant]
WO WO2020046813A1 · 2020 [cited by applicant]
WO WO2020123772A1 · 2020 [cited by applicant]
WO WO2020185859A1 · 2020 [cited by applicant]
WO WO2021138498A1 · 2021 [cited by applicant]
Allard et al. Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters 205 (2019) 31-39. Available online May 24, 2018. (Year: 2018). [cited by examiner]
Lupia et al. CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. Stem Cell Reports vol. 10, p. 1412-1425, Apr. 10, 2018. Published: Mar. 15, 2018. (include Supplementary inf… [cited by examiner]
“33rd Annual Meeting & Pre-Conference 2-9,16, Programs of the Society for Immunotherapy of Cancer (SITC 2018)”, Journal for Immunotherapy of Cancer, Biomed Central Ltd, London, UK, vol. 6, No. 1, Nov. 6, 2018 (Nov. 6, 2… [cited by applicant]
“Research 1-15, Poster Presentation Design 2015”, Mar. 29, 2019 (Mar. 29, 2019), pp. 1-1, XP055972348, Retrieved from the Internet: URL:https://arcusbio.com/wp-content/uploads/2020/09/AACR-2019-Biomarkers-poster.pdf> th… [cited by applicant]
Dipti Vijayan et al: “Targeting immunosuppressive adenosine in cancer”, Nature Reviews Cancer, vol. 17, No. 12, Oct. 23, 2017 (Oct. 23, 2017), pp. 709-724, XP055557876, London, ISSN: 1474-175X, DOI: 10.1038/nrc.2017.86. [cited by applicant]
Direnzo Daniel et al: “Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928”, Cancer Research, vol. 79, No. 13_Supplement, Jul. 1, 2019 (Jul. 1, 2019), pp. 3168-3168, XP055972… [cited by applicant]
European Patent Office Search Report on EP application 20782135.6 dated Nov. 22, 2022 (16 pages). [cited by applicant]
Extended European Search Report issued in connection with EP Appl. Ser. No. 20770898.3 dated Oct. 17, 2022. [cited by applicant]
Le et al: “CD73 inhibition enhances the effect of anti-PD-1 therapy on KRAS-mutated pancreatic cancer model”, Cancer Immunology Research Jul. 2014; AACR Special Conference on Tumor Immunology and Immunotherapy, Nov. 17,… [cited by applicant]
Pedraza-Farina Laura G: “Mechanisms of Oncogenic Cooperation in Cancer Initiation and Metastasis”, Yale Journal of Biology and Medicine, Jan. 1, 2006 (Jan. 1, 2006), pp. 95-103, XP055967921, Retrieved from the Internet:… [cited by applicant]
Roberto Leone et al: “Targeting adenosine 1,3-6, for cancer immunotherapy”, 10-12, Journal for Immunotherapy of Cancer, 15,16, Biomed Central Ltd, London, UK, vol. 6, No. 1, Jun. 18, 2018 (Jun. 18, 2018), pp. 1-9, XP021… [cited by applicant]
Young Arabella et al: “Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis”, Cancer research, vol. 77, No. 17, Sep. 1, 2017 (Sep. 1, 2017), pp. 4684-4696, XP055798544, 2019 San Antonio Breast… [cited by applicant]
U.S. Appl. No. 17/193,473, filed Mar. 5, 2021, Lawson et al. [cited by applicant]
U.S. Appl. No. 17/346,918, filed Jun. 14, 2021, Beatty et al. [cited by applicant]
U.S. Appl. No. 17/507,921, filed Oct. 22, 2021, Beatty et al. [cited by applicant]
International Search Report and Written Opinion dated Oct. 14, 2021 in PCT/US2020/025242, 11 pages. [cited by applicant]
International Search Report and Written Opinion dated Sep. 23, 2021 in PCT/US2020/022028, 8 pages. [cited by applicant]
Mittal et al., “Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor,” Cancer Research, Jul. 1, 2014, 74(14):3652-3658. [cited by applicant]
Stagg et al., “Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis,” PNAS, Jan. 26, 2010, 107(4):1547-1552. [cited by applicant]
Stagg et al., “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene, Jul. 26, 2010, 29(39):5346-5358. [cited by applicant]
Azambuja et al., CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. Molecular Neurobiology (2019) 56:3260-3279, XP036763020. [cited by applicant]
Cushman et al., Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance), Clin Cancer Res. 2015; 21(5): 1078-1086. [cited by applicant]
DiRenzo et al, Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928, Journal for Immuno Therapy of Cancer 2018, 6(Suppl… [cited by applicant]
DiRenzo et al., Abstract 3168: Methods for assessment of the “adenosine fingerprint” in clinical trials of AB928, Cancer Res (2019) 79 (13_Supplement): 3168. [cited by applicant]
Gao et al., CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity, BMC Cancer (2017) 17:135, XP093203406. [cited by applicant]
Häusler et al., Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immun… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/025242 dated Sep. 28, 2021. 9 pages. [cited by applicant]
Linden et al., Purine Release, Metabolism, and Signaling in the Inflammatory Response, Annual Review of Immunology 2019, vol. 37, pp. 325-347. [cited by applicant]
Rao et al., Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer, British Journal of Cancer (2017), 116, pp. 227-236. [cited by applicant]
Tsuji et al., Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis, British Journal of Cancer (2012) 106, 126-132. [cited by applicant]
Turcotte et al., CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer, Cancer Res 2015; 75(21); 4494-4503. [cited by applicant]
Wu et al., High expression of CD73 as a poor prognostic biomarker in human colorectal cancer, Journal of Surgical Oncology 2012; 106:130-137. [cited by applicant]
Yu et al., Extracellular 5′-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3B/B-catenin/cyclinD1 signaling pathway, International Journal of Cancer 2018, vol. 142, No. 5, pp. 959-967, XP09… [cited by applicant]
Zhou et al., The distinct role of CD73 in the progression of pancreatic cancer, Journal of Molecular Medicine (2019) 97:803-815. [cited by applicant]
Morello et al., “Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab,” J. Transl. Med., Dec. 4, 2017, 15:244, 1-9. [cited by applicant]
Liu et al., Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor, Oncotarget 2013, vol. 4, No. 12, p. 2366-2382. [cited by applicant]
OVCAR-3, Cellosaurus, [date of retrieval: Apr. 5, 2024], cellosaurus.org/CVCL_0465.txt, 8 pages. [cited by applicant]
SK-OV-3, Cellosaurus, [date of retrieval: Apr. 5, 2024], cellosaurus.org/CVCL_0532.txt, 8 pages. [cited by applicant]
Wainberg et al., ARC-8: Phase 1/1b Randomized Study of Quemliclustat + Gemcitabine/Nab-Paclitaxel ± Zimberelimab in Patients With Treatment-Naive Metastatic Pancreatic Adenocarcinoma, Jan. 2024. [cited by applicant]
Zhao et al., Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival, Pancreatology 2021, 21(5): 942-949. [cited by applicant]